Accentia Biopharmaceuticals Inc (1310094) SEC Filing 8-K Material Event for the period ending Tuesday, October 9, 2012

Accentia Biopharmaceuticals Inc

CIK: 1310094

View differences made from one to another to evaluate Accentia Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Accentia Biopharmaceuticals Inc.


Assess how Accentia Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1310094
Form Type: 8-K Corporate News
Accession Number: 0001193125-12-423516
Submitted to the SEC: Mon Oct 15 2012 5:12:33 PM EST
Accepted by the SEC: Mon Oct 15 2012
Period: Tuesday, October 9, 2012
Industry: Pharmaceutical Preparations
  1. New Agreement
  2. New Financial Obligation
  3. Unregistered Sales

External Resources:

Bookmark the Permalink: